Editor’s note: A recording of the conversation is embedded below.
Every week, STAT+ subscribers get access to exclusive conversations with biotech, pharma, and health tech leaders. This week, STAT general assignment reporter and associate editorial director of events Nicholas St. Fleur will be joined by Fouad Namouni, president of research and development at Blueprint Medicines. They will be discussing Blueprint’s work in making targeted cancer drugs, the future of oncology, and of course be taking your questions live.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
